Review Article

Honey as a Potential Natural Anticancer Agent: A Review of Its Mechanisms

Sarfraz Ahmed and Nor Hayati Othman

Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

Correspondence should be addressed to Nor Hayati Othman; hayati@kb.usm.my

Received 9 July 2013; Revised 8 October 2013; Accepted 21 October 2013

Academic Editor: Tung-Sheng Chen

Copyright © 2013 S. Ahmed and N. H. Othman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The main treatment for cancer is by using chemotherapy and radiotherapy which themselves are toxic to other viable cells of the body. Recently, there are many studies focusing on the use of natural products for cancer prevention and treatment. Of these natural products, honey has been extensively researched. The mechanism of the anti-cancer activity of honey as chemopreventive and therapeutic agent has not been completely understood. The possible mechanisms are due to its apoptotic, antiproliferative, antitumor necrosis factor (anti-TNF), antioxidant, anti-inflammatory, estrogenic and immunomodulatory activities. We collate the findings of several studies published in the literature in order to understand the mechanism of its action.

1. Introduction

Annually cancer is diagnosed in approximately 11 million people causing 7.6 million deaths worldwide [1]. Cancer is a multistep process. It starts as an onset from a single transformed cell. Its genesis is characterized by the swift proliferation, invasion, and metastasis [2]. This dynamic process is activated by various carcinogens, tumor promoters, and inflammatory agents. The whole modulation is controlled through the transcription factors, proapoptotic proteins, antiapoptotic proteins, protein kinases, cell cycle proteins, cell-adhesion molecules, cyclooxygenase-2 (COX-2), and other molecular targets [2–4].

The standard treatments against cancer are surgery, radiotherapy, and chemotherapy. These modalities are beset with serious side effects [5]. New targets for cancer treatment focus on interfering with specific targeted molecules needed in carcinogenesis [6].

Natural products such as honey have potential anticancer effect [7]. Honey is composed of various sugars, flavonoids, phenolic acids, enzymes, amino acids, proteins, and miscellaneous compounds (Table 1). Its composition varies according to floral sources and origin [8]. It has been shown to have anti-inflammatory [9], antimicrobial [10], antimutagenic [11], antioxidant [12], and antitumor [7,13,14] effects. The phenolic contents of honey have been reported to have antileukemic activity against different types of leukemic cell lines [15]. Its anticancer activity has been proved against various cancer cell lines and tissues, such as breasts [14,16–19], colorectal [20], renal [21], prostate [17], endometrial [17], cervical [19] and oral cancer [22].

Honey potentiates the antitumor activity of chemotherapeutic drugs such as 5-fluorouracil and cyclophosphamide [18]. Studies exhibiting anticancer effect of honey range from tissue cultures [17,19,20,22,23] and animal models [14,16,18,24] to clinical trials [25]. Polyphenols in honey are considered as one of the main factors responsible for the anticancer activity of honey [15,26].

This review presents current progress in understanding the mechanism of anticancer activity of honey.

2. Honey and Its Apoptotic Activity

Two characteristics of cancer cells are uncontrolled cellular proliferation and inadequate apoptotic turnover [27]. Drugs which are commonly used for cancer treatment are apoptosis inducers [28]. Programmed cell death or apoptosis is categorized into three phases: (a) an induction phase, (b) an effector phase, and (c) a degradation phase [29]. The induction phase stimulates proapoptotic signal transduction cascades through death-inducing signals. Effector phase is committed
3. Honey and Its Antiproliferative Activity

Epithelial cell divides throughout life. The cell cycle comprises three distinguished phases known as G₀, G₁, S, and G₂/M. All the events in the cell cycle are regulated and monitored by several different proteins. The control panel of cell cycle comprises cyclins and cyclin-dependent kinases. The G₁/S phase transition is a vital regulatory point where cell’s fate is destined for quiescence, proliferation, differentiation and apoptosis [32]. Overexpression and dysregulation of cell cycle growth factors such as cyclin D1 and cyclin-dependent kinases (CDK) are linked with tumorigenesis [32]. The loss of this regulation is the hallmark of cancer [32]. The nuclear protein Ki-67 is a novel marker to probe the “growth fraction” of cell proliferation. It is absent in the resting phase (G₀) but expressed during the cell cycle in all the proliferation phases (G₁, S, G₂, and mitosis) [33].

Honey has been shown to affect cell cycle arrest. Administration of honey mixed with Aloe vera solution showed a marked decrease in expression of Ki67-LI in tumor cells in rats [14]. It suggests that honey therapy could lead to lowering tumor cell proliferation by arresting cell cycle [14]. Honey and its several components (like flavonoids and phenolics) are reported to block the cell cycle of colon [20], glioma [34], and melanoma [35] cancer cell lines in G₀/G₁ phase. This inhibitory effect on tumor cell proliferation follows the downregulation of many cellular pathways via tyrosine cyclooxygenase, ornithine decarboxylase, and kinase [20, 34–36]. The results of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and the trypan blue exclusion assays have confirmed that anti-proliferative effect of honey is a dose- and time-dependent manner [35]. Honey or its components mediate inhibition of cell growth due to its perturbation of cell cycle [35, 36]. Cell cycle is also regulated by p53 which is involved in tumor suppression. Honey is reported to be involved in modulation of p53 regulation [20].

4. Honey and Its Effect on Tumor Necrosis Factor (TNF)

Tumor necrosis factor (TNF), have been shown to mediate tumor initiation, promotion, and progression [37]. The proinflammatory effect of TNF is linked to many diseases due to its ability to activate NF-kB [38]. It activates NF-kB, leading to the expression of inflammatory genes like lipooxygenase-2 (LOX-2), cyclooxygenase-2 (COX-2), cell-adhesion molecules, chemokines, inducible nitric oxide synthase (iNOS), and inflammatory cytokines [38]. It is considered as a growth factor for many of the tumor cells [38]. In contradiction, TNF-α has also been shown to be involved in host defense mechanisms as a key cytokine [39]. It has been shown to play a dual role, beneficial and deleterious for the promotion or inhibition of infectious diseases [39, 40].

Royal jelly (RJ) proteins (apalbumin-1 and apalbumin-2) in honey have antitumor properties. These proteins stimulate a possible natural substance as anticancer agent as many chemotherapeutics currently used are apoptosis inducers.
Evidence-Based Complementary and Alternative Medicine

Figure 1: Apoptosis following caspase 8 and caspase 9 pathways; source [30]. Bcl-2: B cell lymphoma 2 protein; Bid: Bcl-2 associated X proteins; Cyt. C: cytochrome C; Apaf-1: apoptotic protease activating factor; IAP: inhibitor of apoptosis proteins; Caspase 3—caspase protein that interacts with caspase 8 and caspase 9.

Figure 2: The effect of honey on apoptotic pathway. Honey exerts apoptotic effect through upregulation and modulation of proapoptotic proteins (p53, Bax, caspase 3, and caspase 9) and downregulation of antiapoptotic proteins (Bcl-2) [14, 23, 31]. Bcl-2: B cell lymphoma 2 protein; Cyt. C: cytochrome C; Apaf-1—apoptotic protease activating factor I; TNF: tumor necrosis factor; TRAIL: TNF related apoptosis-inducing ligand; TRADD: TNFR associated death domain protein.

macrophages to release cytokines TNF-α, interleukin-1 (IL-1) and interleukin-6 (IL-6) [41, 42]. Pasture, jelly bush, and Manuka honeys (at concentrations of 1% w/v) stimulate monocytes to release tumor necrosis factor-alpha and interleukin- (IL-) 1β and IL-6 [43, 44]. The possible mechanism involves the binding of TNF-R to TNF-α and adaptor protein such as TNFR associated death domain protein (TRADD), TNF receptor associated factor (TRAF), and receptor-interacting protein (RIP) to regulate apoptosis and inflammation through these cytokines [45]. This TNF-α release can play a pivotal role as a key cytokine to regulate important cellular processes such as apoptosis, cell proliferation, and inflammation [41, 45].

5. Honey and Its Anti-Inflammatory and Immunomodulatory Activities

Chronic inflammation is linked to cancer formation. Excessive or prolonged inflammation can prevent healing by damaging tissues. Honey exhibits anti-inflammatory response [46]. The literature shows that it reduces inflammation when applied in cell cultures [47], animal models [48, 49],
and clinical trials [46, 50]. The inflammatory process is induced by various types of chemicals and/or biological agents including proinflammatory enzymes and cytokines [51]. The enzyme cyclooxygenase-2 (COX-2) in inflammatory process catalyzes the metabolism of arachidonic acid to prostaglandin [52, 53]. Anomalous arachidonic acid metabolism is involved in carcinogenesis and inflammation [54]. COX-2 is overexpressed in premalignant and malignant conditions [54]. Phenolic compounds in honey are responsible for anti-inflammatory activity [55]. The mechanism involves the suppression of the proinflammatory activities of COX-2 and/or inducible nitric oxide synthase (iNOS) through these phenolic compounds or flavonoids [53]. Honey and its components have been documented to be involved in regulation of proteins such as ornithine decarboxylase, tyrosine kinase, iNOS, and COX-2 [56, 57].

Manuka, Pasture, Nigerian Jungle, and royal jelly honeys are found to increase IL-1β, IL-6, and TNF-α production [16, 44, 58]. This immunomodulatory and immunoprotective activity of honey is often linked to anticancer action [16, 59]. Honey stimulates antibodies, B and T lymphocytes, neutrophils, monocytes, eosinophils, and natural killer cells (NK-cells) production during primary and secondary immune responses in tissue culture [59–62]. It has been shown that honey stimulates macrophages, T-cells, and B-cells to provoke antitumor effect [59].

Sugars when ingested are slowly absorbed resulting in the formation of short chain fatty acid (SCFA) fermentation products [63]. It is a probable mechanism that the ingestion of honey may result in SCFA formation [64]. Research has established that, either directly or indirectly, SCFA have immunomodulatory actions [65]. Thus, honey may stimulate the immune system via these fermentable sugars [66]. A sugar, nigerooligosaccharides (NOS), present in honey has been found to have immunopotentiating activity [67]. Nonsugar components of honey may also be responsible for immunomodulation [66].

6. Honey and Its Antioxidant Activity

The role of oxidative stress involving free radicals in the carcinogenic process is well established [68]. Reactive oxygen species (ROS) and reactive nitrogen species (RNS), such as hydroxyl radical ("OH), superoxide (O₂⁻), hydrogen peroxide (H₂O₂), nitric oxide (NO), peroxynitrite (ONO2⁻), and others, are oxidative stress agents which damage lipids, proteins, and DNA in cells [69]. Cells exhibit defense system against oxidative damage. This defense system consists of antioxidants or oxidative protective agents such as catalase, superoxide dismutase, peroxidase, ascorbic acid, tocopherol, and polyphenols [70]. Antioxidants acting as free radical scavengers may inhibit the cancer process in vivo [70]. The exact antioxidant mechanism is unknown, but the proposed mechanism is through hydrogen donation, free radical sequestration, metallic ion chelation, flavonoids substrates for hydroxyl and superoxide radical actions [71]. The antioxidant capacity of honey contributes to the prevention of several acute and chronic disorders such as diabetes [72], inflammatory disorders [73], cardiovascular diseases [74], and cancer [75, 76]. The phenolic acids and flavonoids are responsible for the well-established antioxidant activity of honey [77].

The antitumor effect of honey may be attributed to its antioxidant activity [75, 76]. An enhanced antioxidant status with apoptosis has been observed in hepatocellular carcinoma cells [75]. Daily consumption of 1.2 g/kg body weight of honey has been shown to elevate the amount and the activity of antioxidant agents such as beta-carotene, vitamin C, glutathione reductase, and uric acid [60].

7. Honey and Its Antiμutagenic Activity

Mutagenicity, the ability to induce genetic mutation, is interlinked with carcinogenicity [78]. Honey is shown to have a strong antiμutagenic agent and hence has anticarcinogenic property [79]. The effect of honey on radiation (UV or γ) exposed Escherichia coli cells shows SOS response (SOS is an error prone repair pathway contributing to mutagenicity) [79]. A study was performed to knock out some important genes such as umuC, recA, and umuD involved in SOS mediated mutagenesis. These changes are significantly inhibited in the presence of honey confirming its strong antiμutagenic effect [79]. Honeys from different floral origins exhibit inhibition of Trp-p-1 mutagenicity [11].

8. Honey and Its Estrogenic Modulatory Activity

Estrogen is involved in number of cancers [80]. Honey modulates estrogen by its antagonistic action. It may be useful in estrogen-dependent cancers such as breasts and endometrial cancers [17]. Estrogen receptors tie to estrogens to dimerize and then translocate into the nuclei. These complexes then bind to the specific DNA base sequences called estrogen-response elements (EREs) resulting in transcription and translation of the estrogenic effect in the targeted tissue [80]. This signaling cascade induced by estrogens may be modulated at any stage [80]. Honeys from various floral sources are reported to mediate estrogenic effects via the modulation of estrogen receptor activity [17, 81]. This effect is attributed to its phenolic content [17]. Greek honey extracts exert estrogen agonistic effect at high concentrations (20–100 lg/mL) and antagonistic effect at low concentrations (0.2–5 µg/mL) [17].

9. Conclusion

Evidence is growing that honey may have the potential to be anticancer agent through several mechanisms (Figure 3). Though the full mechanism is yet to be fully understood, studies have shown that honey has anticancer effect through its interference with multiple cell-signaling pathways, such as inducing apoptosis, antiproliferative, anti-inflammatory, and antimutagenic pathways. Honey modulates the body immune system. There are still many unanswered questions; why sugar is carcinogenic, while honey which is basically sugar has...
anticarcinogenic properties. Honey of different floral sources may give different effects. More research is needed to improve our understanding of the positive effect of honey and cancer. What is seen in cell cultures or animal experimentations may not apply to humans. Prospective randomized controlled clinical trials are needed to validate the authenticity of honey either alone or as adjuvant therapy.

Acknowledgment

The authors would like to acknowledge USM RU Grant 1001/PPSP/813051 for the publication fees.

References

[1] Cancer, 2013, http://www.who.int/cancer/en/.
[2] S. Shishodia, S. Majumdar, S. Banerjee, and B. B. Aggarwal, “Ursolic acid inhibits nuclear factor-κB activation induced by carcinogenic agents through suppression of IkBα kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1,” Cancer Research, vol. 63, no. 15, pp. 4375–4383, 2003.
[3] J. Wang and M. J. Lenardo, “Roles of caspases in apoptosis, development, and cytokine maturation revealed by homoygous gene deficiencies,” Journal of Cell Science, vol. 113, no. 5, pp. 753–757, 2000.
[4] B. B. Aggarwal and S. Shishodia, “Molecular targets of dietary agents for prevention and therapy of cancer,” Biochemical Pharmacology, vol. 71, no. 10, pp. 1397–1421, 2006.
[5] R. V. J. Chari, “Targeted cancer therapy: conferring specificity to cytotoxic drugs,” Accounts of Chemical Research, vol. 41, no. 1, pp. 98–107, 2008.
[6] B. Goldman, “Combinations of targeted therapies take aim at multiple pathways,” Journal of the National Cancer Institute, vol. 95, no. 22, pp. 1656–1657, 2003.
[7] N. H. Othman, “Honey and cancer: sustainable inverse relationship particularly for developing nations—a review,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 410406, 10 pages, 2012.
[8] N. Gheldof, X. H. Wang, and N. J. Engeseth, “Identification and quantification of antioxidant components of honeys from various floral sources,” Journal of Agricultural and Food Chemistry, vol. 50, no. 21, pp. 5870–5877, 2002.
[9] R. A. Cooper, P. Molan, L. Krishnamoorthy, and K. Harding, “Manuka honey used to heal a recalcitrant surgical wound,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 20, no. 10, pp. 758–759, 2001.
[10] O. Sherlock, A. Dolan, R. Athman et al., “Comparison of the antimicrobial activity of Ulmo honey from Chile and Manuka honey against methicillin-resistant Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa,” BMC Complementary and Alternative Medicine, vol. 10, article 47, 2010.
[11] X. H. Wang, L. Andrae, and N. J. Engeseth, “Antimutagenic effect of various honeys and sugars against Trp-δ-p-1,” Journal of Agricultural and Food Chemistry, vol. 50, no. 23, pp. 6923–6928, 2002.
[12] M. Al-Mamary, A. Al-Meeri, and M. Al-Habori, “Antioxidant activities and total phenolics of different types of honey,” Nutrition Research, vol. 22, no. 9, pp. 1041–1047, 2002.
[13] T. Swellam, N. Miyanaga, M. Onozawa et al., “Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies,” International Journal of Urology, vol. 10, no. 4, pp. 213–219, 2003.
[14] R. Tomasin and M. C. Cintra Gomes-Marcondes, “Oral administration of Aloe vera and honey reduces Walker tumour growth by decreasing cell proliferation and increasing apoptosis in tumour tissue,” Phytotherapy Research, vol. 25, no. 4, pp. 619–623, 2011.
[15] M. B. Abubakar, W. Z. Abdullah, S. A. Sulaiman, and A. B. Suen, “A review of molecular mechanisms of the anti-leukemic effects of phenolic compounds in honey,” International Journal of Molecular Sciences, vol. 13, no. 11, pp. 15054–15073, 2012.
[16] M. Fukuda, K. Kobayashi, Y. Hirono et al., “Jungle honey enhances immune function and antitumor activity,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 908743, 8 pages, 2011.
[17] A. V. Tsiapara, M. Jaakkola, I. Chinou et al., “Bioactivity of Greek honey extracts on breast cancer (MCF-7), prostate cancer (PC-3) and endometrial cancer (Ishikawa) cells: profile analysis of extracts,” Food Chemistry, vol. 116, no. 3, pp. 702–708, 2009.
[18] N. V. Gribel and V. G. Pashinskii, “The antitumor properties of honey,” Voprosy Onkol ogii, vol. 36, no. 6, pp. 704–709, 1990.
[19] A. N. Fauzi, M. N. Norazmi, and N. S. Yaacob, “Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines,” Food and Chemical Toxicology, vol. 49, no. 4, pp. 871–878, 2011.
[20] S. K. Jaganathan and M. Mandal, “Honey constituents and their apoptotic effect in colon cancer cells,” Journal of ApiProduct and ApiMedcial Science, vol. 1, no. 2, pp. 29–36, 2009.
[21] S. K. Jaganathan and M. Mandal, “Honey constituents and their apoptotic effect in colon cancer cells,” Journal of ApiProduct and ApiMedical Science, vol. 1, no. 2, pp. 29–36, 2009.
[22] S. Samarghandian, J. T. Afshari, and S. Davoodi, “Honey and honey reduces Walker tumour growth by decreasing cell proliferation and increasing apoptosis in tumour tissue,” Phytotherapy Research, vol. 25, no. 4, pp. 619–623, 2011.
[23] A. V. Tsiapara, M. Jaakkola, I. Chinou et al., “Bioactivity of Greek honey extracts on breast cancer (MCF-7), prostate cancer (PC-3) and endometrial cancer (Ishikawa) cells: profile analysis of extracts,” Food Chemistry, vol. 116, no. 3, pp. 702–708, 2009.
[24] N. V. Gribel and V. G. Pashinskii, “The antitumor properties of honey,” Voprosy Onkol ogii, vol. 36, no. 6, pp. 704–709, 1990.
[25] A. N. Fauzi, M. N. Norazmi, and N. S. Yaacob, “Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines,” Food and Chemical Toxicology, vol. 49, no. 4, pp. 871–878, 2011.
[26] S. K. Jaganathan and M. Mandal, “Honey constituents and their apoptotic effect in colon cancer cells,” Journal of ApiProduct and ApiMedical Science, vol. 1, no. 2, pp. 29–36, 2009.
[27] S. Samarghandian, J. T. Afshari, and S. Davoodi, “Honey and honey reduces Walker tumour growth by decreasing cell proliferation and increasing apoptosis in tumour tissue,” Phytotherapy Research, vol. 25, no. 4, pp. 619–623, 2011.
[23] S. K. Jaganathan and M. Mandal, “Involvement of non-protein thiols, mitochondrial dysfunction, reactive oxygen species and p53 in honey-induced apoptosis,” Investigational New Drugs, vol. 28, no. 5, pp. 624–633, 2010.

[24] N. Orsolic, A. Knezevic, L. Sver, S. Terzic, B. K. Hackenberger, and I. Basic, “Influence of honey bee products on transplantable murine tumours,” Veterinary and Comparative Oncology, vol. 1, no. 4, pp. 216–226, 2003.

[25] L. I. Smirnova, E. I. Filatova, A. N. Susorov, and E. N. Bylinskaya, “The use of therapeutic/prophylactic dragee “honey laminolact” in radiotherapy of uterine tumors,” Voprosy Onkologii, vol. 46, no. 6, pp. 748–750, 2000.

[26] S. K. Jaganathan and M. Mandal, “Antiproliferative effects of honey and of its polyphenols: a review,” Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 830616, 13 pages, 2009.

[27] D. W. Nicholson, “From bench to clinic with apoptosis-based therapeutic agents,” Nature, vol. 407, no. 6805, pp. 810–816, 2000.

[28] W. C. Earnshaw, “Nuclear changes in apoptosis,” Current Opinion in Cell Biology, vol. 7, no. 3, pp. 337–343, 1995.

[29] S. A. Susin, N. Zamzami, and G. Kroemer, “Mitochondria and regulators of apoptosis: doubt no more,” Biochimica et Biophysica Acta, vol. 1366, no. 1-2, pp. 151–165, 1998.

[30] M. H. Andersen, J. C. Becker, and P. T. Straten, “Regulators of apoptosis: suitable targets for immune therapy of cancer,” Nature Reviews Drug Discovery, vol. 4, no. 5, pp. 399–409, 2005.

[31] M. J. Fernandez-Cabezudo, R. El-Kharrag, B. K. Hackenberg, and J. Gerdes, “The Ki-67 protein: from the known and the unknown,” Journal of Cellular Physiology, vol. 182, no. 3, pp. 311–322, 2000.

[32] Y. J. Lee, H. Kuo, C. Chu, C. Wang, W. Lin, and T. Tseng, “Synthesis and inhibitory activity against COX-2 catalyzed prostaglandin production of chrysin derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 5, pp. 1165–1167, 2004.

[33] J. A. Diehl, “Cycling to cancer with cyclin D1,” Cancer Biology and Therapy, vol. 1, no. 3, pp. 226–231, 2002.

[34] T. Slolzen and J. Gerdes, “The Ki-67 protein: from the known and the unknown,” Journal of Cellular Physiology, vol. 182, no. 3, pp. 973–981, 2010.

[35] N. Oršolić, V. Benković, D. Lisić, D. Đikić, J. Erhardt, and A. H. Knežević, “Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan,” Medical Oncology, vol. 27, no. 4, pp. 1346–1358, 2010.

[36] R. J. Moore, D. M. Owens, G. Stamp et al., “Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis,” Nature Medicine, vol. 5, no. 7, pp. 828–831, 1999.

[37] B. J. Sugarman, B. B. Aggarwal, and P. E. Hass, “Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro,” Science, vol. 230, no. 4728, pp. 943–945, 1985.

[38] S. Chouaib, D. Branlec, and W. A. Buurman, “More insights into the complex physiology of TNF,” Immunology Today, vol. 12, no. 5, pp. 141–142, 1991.

[39] D. Schlüter and M. Deckert, “The divergent role of tumor necrosis factor receptors in infectious diseases,” Microbes and Infection, vol. 2, no. 10, pp. 1285–1292, 2000.

[40] J. Šimůth, K. Bíliková, E. Kováčová, Z. Kuzmová, and W. Schroder, “Immunochemical approach to detection of adulation in honey: physiologically active royal jelly protein stimulating TNF-α release is a regular component of honey,” Journal of Agricultural and Food Chemistry, vol. 52, no. 8, pp. 2154–2158, 2004.

[41] J. Majtán, E. Kováčová, K. Bíliková, and J. Šimůth, “The immunostimulatory effect of the recombinant apalbumin 1-major honeybee royal jelly protein-on TNFa release,” International Immunopharmacology, vol. 6, no. 2, pp. 269–278, 2006.

[42] A. J. Tonks, R. A. Cooper, K. P. Jones, S. Blair, J. Parton, and A. Tonks, “Honey stimulates inflammatory cytokine production from monocytes,” Cytokine, vol. 21, no. 5, pp. 242–247, 2003.

[43] A. Tonks, R. A. Cooper, A. J. Price, P. C. Molan, and K. P. Jones, “Stimulation of TNF-α release in monocytes by honey,” Cytokine, vol. 14, no. 4, pp. 240–242, 2001.

[44] D. J. MacEwan, “TNF ligands and receptors—a matter of life and death,” The British Journal of Pharmacology, vol. 135, no. 4, pp. 855–875, 2002.

[45] M. Subrahmanyan, “A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine,” Burns, vol. 24, no. 2, pp. 157–161, 1998.

[46] M. Candiracci, E. Piatti, M. Dominguez-Barragán et al., “Anti-inflammatory activity of a honey flavonoid extract on lipopolysaccharide-activated N13 microglial cells,” Journal of Agricultural and Food Chemistry, vol. 60, no. 50, pp. 12304–12311, 2012.

[47] A. G. Leong, P. M. Herst, and J. L. Harper, “Indigenous New Zealand honeys exhibit multiple anti-inflammatory activities,” Innate Immunity, vol. 18, no. 3, pp. 459–466, 2012.

[48] Y. Bülser, D. Bugra, S. Yamaner, T. Bulut, U. Cevikbas, and U. Turkoglu, “Could honey have a place in colitis therapy? Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation,” Digestive Surgery, vol. 19, no. 4, pp. 306–311, 2002.

[49] N. S. Al-Waili and N. S. Boni, “Natural honey lowers plasma prostaglandin concentrations in normal individuals,” Journal of Medicinal Food, vol. 6, no. 2, pp. 129–133, 2003.

[50] T. T. Dao, Y. S. Chi, J. Kim, H. P. Kim, S. Kim, and H. Park, “Synthesis and inhibitory activity against COX-2 catalyzed prostaglandin production of chrysin derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 5, pp. 1165–1167, 2004.

[51] D. E. Griswold and J. L. Adams, “Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date,” Medicinal Research Reviews, vol. 16, no. 2, pp. 181–206, 1996.

[52] H. Cho, C. Yun, W. Park et al., “Modulation of the activity of pro-inflammatory enzymes, COX-2 and iNOS, by chrysin derivatives,” Pharmacological Research, vol. 49, no. 1, pp. 37–43, 2004.

[53] J. Hong, T. J. Smith, C. Ho, D. A. August, and C. S. Yang, “Effects of purified green and black tea polyphenols on cyclooxygenase-and lipoxygenase-dependent metabolism of arachidonic acid in human colon mucosa and colon tumor tissues,” Biochemical Pharmacology, vol. 62, no. 9, pp. 1175–1183, 2001.

[54] M. Viuda-Martos, Y. Ruiz-Navaajas, J. Fernández-López, and J. A. Pérez-Alvarez, “Functional properties of honey, propolis, and royal jelly,” Journal of Food Science, vol. 73, no. 9, pp. R117–R124, 2008.

[55] S. Z. Hussein, K. M. Yusoff, S. Makpol, and Y. A. M. Yusof, “Gelam honey inhibits the production of pro-inflammatory,
mediators NO, PGE\(_2\), TNF-alpha, and IL-6 in carrageenan-induced acute paw edema in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 109636, 13 pages, 2012.

[57] J. R. Araújo, P. Gonçalves, and F. Martel, “Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines,” Nutrition Research, vol. 31, no. 2, pp. 77–87, 2011.

[58] M. Timm, S. Bartelt, and E. W. Hansen, “Immunomodulatory effects of honey cannot be distinguished from endotoxin,” Cytokine, vol. 42, no. 1, pp. 113–120, 2008.

[59] W. Y. Attia, M. S. Gabry, K. A. El-Shaikh, and G. A. Othman, “The anti-tumor effect of bee honey in Ehrlich ascite tumor model of mice is coincided with stimulation of the immune cells,” The Egyptian Journal of Immunology, vol. 15, no. 2, pp. 169–183, 2008.

[60] N. S. Al-Waili, “Effects of daily consumption of honey solution on hematological indices and blood levels of minerals and enzymes in normal individuals,” Journal of Medicinal Food, vol. 6, no. 2, pp. 135–140, 2003.

[61] N. Abuharfeil, R. Al-Oran, and M. Abo-Shehada, “The effect of bee honey on the proliferative activity of human B- and T- lymphocytes and the activity of phagocytes,” Food and Agricultural Immunology, vol. 11, no. 2, pp. 169–177, 1999.

[62] N. S. Al-Waili and A. Haq, “Effect of honey on antibody production against thymus-dependent and thymus-independent antigens in primary and secondary immune responses,” Journal of Medicinal Food, vol. 7, no. 4, pp. 491–494, 2004.

[63] H. Kruse, B. Kleessen, and M. Blaut, “Effects of inulin on faecal bifidobacteria in human subjects,” The British Journal of Nutrition, vol. 82, no. 5, pp. 375–382, 1999.

[64] M. L. Sanz, N. Polemis, V. Morales et al., “In vitro investigation into the potential prebiotic activity of honey oligosaccharides,” Journal of Agricultural and Food Chemistry, vol. 53, no. 8, pp. 2914–2921, 2005.

[65] P. D. Schley and C. J. Field, “The immune-enhancing effects of dietary fibres and prebiotics,” The British Journal of Nutrition, vol. 87, supplement 2, pp. S221–S230, 2002.

[66] L. M. Chepulis, “The effect of honey compared to sucrose, mixed sugars, and a sugar-free diet on weight gain in young rats,” Journal of Food Science, vol. 72, no. 3, pp. S224–S229, 2007.

[67] S. Murasaki, K. Muroyama, Y. Yamamoto, T. Liu, and Y. Yoshikai, “Nigerooligosaccharides augments natural killer activity of hepatic mononuclear cells in mice,” International Immunopharmacology, vol. 2, no. 1, pp. 151–159, 2002.

[68] J. M. C. Gutteridge and B. Halliwell, “Comments on review of free radicals in biology and medicine, second edition, by Barry Halliwell and John M. C. Gutteridge,” Free Radical Biology and Medicine, vol. 12, no. 1, pp. 93–95, 1992.

[69] S. Orrenius, V. Gogvadze, and B. Zhivotovsky, “Mitochondrial oxidative stress: implications for cell death,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 143–183, 2007.

[70] G. Block, “The data support a role for antioxidants in reducing cancer risk,” Nutrition Reviews, vol. 50, no. 7, pp. 207–213, 1992.

[71] S. A. B. E. van Acker, D. van den Berg, M. N. J. L. Tromp et al., “Structural aspects of antioxidant activity of flavonoids,” Free Radical Biology and Medicine, vol. 20, no. 3, pp. 331–342, 1996.

[72] O. O. Erejuwa, S. A. Sulaiman, M. S. Wahab, K. N. S. Sirajudeen, M. S. M. D. Salleh, and S. Gurtu, “Antioxidant protection of Malaysian tualang honey in pancreas of normal and streptozotocin-induced diabetic rats,” Annales d’Endocrinologie, vol. 71, no. 4, pp. 291–296, 2010.

[73] E. K. Akkol, D. D. Orhan, I. Gürübüz, and E. Yesilada, “In vivo activity assessment of a “honey-bee pollen mix” formulation,” Pharmaceutical Biology, vol. 48, no. 3, pp. 253–259, 2010.

[74] M. K. Rakha, Z. I. Nabil, and A. A. Hussein, “Cardioactive and vasoactive effects of natural wild honey against cardiac malperformance induced by hyperadrenergetic activity,” Journal of Medicinal Food, vol. 11, no. 1, pp. 91–98, 2008.

[75] M. I. Hassan, G. M. Mabrouk, H. H. Shehata, and M. M. Aboelhussein, “Antineoplastic effects of bee honey and Nigella sativa on hepatocellular carcinoma cells,” Integrative Cancer Therapies, vol. 11, no. 4, pp. 354–363, 2012.

[76] S. Dragan, T. Nicola, R. Ilina et al., “Role of multi-component functional foods in the complex treatment of patients with advanced breast cancer,” Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi, vol. III, no. 4, pp. 877–884, 2007.

[77] T. Nagai, M. Sakai, R. Inoue, H. Inoue, and N. Suzuki, “Antioxidative activities of some commercially honeys, royal jelly, and propolis,” Food Chemistry, vol. 75, no. 2, pp. 237–240, 2001.

[78] T. Tsutsui, N. Hayashi, H. Maizumi, J. Huff, and J. C. Bartlett, “Benzene-, catechol-, hydroquinone- and phenol-induced cell transformation, gene mutations, chromosome aberrations, aneuploidy, sister chromatid exchanges and unscheduled DNA synthesis in Syrian hamster embryo cells,” Mutation Research, vol. 373, no. 1, pp. 113–123, 1997.

[79] S. Saxena, S. Gautam, G. Maru, D. Kawle, and A. Sharma, “Suppression of error prone pathway is responsible for antimutagenic activity of honey,” Food and Chemical Toxicology, vol. 50, no. 3-4, pp. 625–633, 2012.

[80] C. J. Gruber, W. Tschugguel, C. Schneegberger, and J. C. Huber, “Production and actions of estrogens,” The New England Journal of Medicine, vol. 346, no. 5, pp. 340–352, 2002.

[81] S. S. M. Zaid, S. A. Sulaiman, K. N. M. Sirajudeen, and N. H. Othman, “The effects of tualang honey on female reproductive organs, tibia bone and hormonal profile in ovariectomised rats—animal model for menopause,” BMC Complementary and Alternative Medicine, vol. 10, article 82, 2010.

[82] T. Eteraf-Oskouei and M. Najafi, “Traditional and modern uses of natural honey in human diseases: a review,” Iranian Journal of Basic Medical Sciences, vol. 16, no. 6, pp. 731–742, 2013.

[83] S. Bogdanov, T. Judecic, R. Sieber, and P. Gallmann, “Honey for nutrition and health: a review,” Journal of the American College of Nutrition, vol. 27, no. 6, pp. 677–689, 2008.